Analyzing the ADAURA Trial of Osimertinib in EGFR+ Lung Cancer
Tony S. K. Mok, BMSc, MD, FRCPC, discusses the ADAURA trial of osimertinib in patients with non–small cell lung cancer.
The Utility of Afatinib in Lung Cancer
Tony S.K. Mok, BMSc, MD, FRCPC, professor, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital Hong Kong, China, discusses the utility of afatinib in patients with lung cancer.
Plasma Testing Approaches for Lung Cancer
Tony S.K. Mok, BMSc, MD, FRCPC, professor, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital Hong Kong, China, discusses different plasma testing approaches for patients with lung cancer.
Improving Lung Cancer Drug Development
Tony S.K. Mok, BMSc, MD, FRCPC, from the Prince of Wales Hospital Hong Kong, China, discusses how to improve the strategy of developing treatments for lung cancer.